#clinical-trial-failure

[ follow ]
#novo-nordisk-stock-decline #glp-1-drug-competition #pharmaceutical-pricing #analyst-downgrades
Healthcare
from24/7 Wall St.
1 day ago

Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low

Novo Nordisk's stock dropped 22% weekly and 56% yearly after CagriSema trial failure and announced price cuts on flagship drugs, causing analyst downgrades and declining Reddit sentiment.
Business
fromSFGATE
4 months ago

Bay Area biotech company once worth $2 billion lays off half of its workers

Alector will lay off about half its staff after its Phase 3 drug latozinemab failed to slow dementia progression, prompting program discontinuation and leadership changes.
[ Load more ]